- $1.28bn
- $1.72bn
- $348.97m
Brief: MannKind Q2 Net Income USD -5.265 Million
MannKind Corp expected to post a loss of 4 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Energy firms, Copper miners, US banks
U.S. STOCKS ON THE MOVE-Coherus, Rivian, Great Ajax
MannKind falls as fire at contract manufacturer's plant to delay drug trial
Brief: Mannkind On June 26, Was Informed Co's Contract Manufacturer Of Clofazimine Inhalation Solution Experienced Fire In Its Manufacturing Unit, Germany
Brief: Mannkind Launches Inhale-3 Study To Address The Most Important Unmet Need Today In Adults Living With Type 1 Diabetes
Brief: MannKind Q1 commercial product sales USD 17.562 million
MannKind Corp reports results for the quarter ended in March - Earnings Summary
Brief: Mannkind Corporation Reports 2023 First Quarter Financial Results
MannKind Corp expected to post a loss of 5 cents a share - Earnings Preview
MannKind Corp expected to post a loss of 5 cents a share - Earnings Preview
Brief: Mannkind Corporation Reports 2022 Fourth Quarter And Full Year Financial Results
Brief: MannKind Reports Q4 revenue $17.44 million
MannKind Corp reports results for the quarter ended in December - Earnings Summary
MannKind Corp expected to post a loss of 6 cents a share - Earnings Preview
MannKind Corp rises on plans to begin lung disease drug study
MannKind Corp reports results for the quarter ended in September - Earnings Summary
Brief: Mannkind Corp Reports 2022 Third Quarter Financial Results